Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01776606 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

A Phase 3 study of Skin Aging, sponsored by Revance Therapeutics.

Completed
Registry status
Phase 3
Development phase
247
Enrollment target
1
Study location

NCT01776606 is a Phase 3 study of Skin Aging that has completed, run by Revance Therapeutics. The registered enrollment target is 247 participants, above the 48-participant average among 9 other Skin Aging trials with a reported enrollment target (415% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01776606, a Phase 3 study of Skin Aging, has completed, sponsored by Revance Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
247 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Botulinum Toxin Type A

Study Locations (1)

Florida

  • Dermatology Research Institute - Coral Gables

Trial Details

FieldValue
Enrollment Target 247 participants
Start Date 2012-12
Est. Completion 2013-05
Phase Phase 3

Sponsor

Revance Therapeutics

27 total trials

What the Registry Record Tells You About NCT01776606

The ClinicalTrials.gov registry entry for NCT01776606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 9 other Skin Aging trials with a reported enrollment target (415% higher). The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Skin Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01776606 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01776606 about?

NCT01776606 is a clinical study titled "Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines". This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.

What is the current status of trial NCT01776606?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2012-12. Estimated completion is 2013-05.

What conditions does trial NCT01776606 study?

This clinical trial studies the following conditions: Skin Aging.

What interventions are being tested in trial NCT01776606?

The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).

Who is sponsoring clinical trial NCT01776606?

This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01776606 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Skin Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.